Fresenius Medical Care AG FMS
Regular-session close
After hours · Nov 19, 4:06 PM ET
- YTD
- -15.49%
- 1 year
- -11.67%
5D -1.10 (-4.96%)
- Market cap
- 10.45B
- Revenue (ttm)
- 19.48B
- Profit margin
- 4.22%
- EPS (ttm)
- 1.73
- Shares out
- 519.02M
- P/E ratio
- 11.64
- Forward P/E
- 7.66
- Dividend
- 0.87 (4.16%)
- Ex-dividend date
- May 22, 2026
- YTD return
- -15.49%
- 1-year return
- -11.67%
- Volume
- 2.10M
- Avg volume
- 1.15M
- Open
- 20.83
- Previous close
- 20.95
- Day's range
- 20.00 – 20.84
- 52-week range
- 20.00 – 26.42
- Beta
- 0.79
- Analysts
- Hold
- Price target
- 21.55 (+7.1%)
- Earnings date
- Feb 23, 2027
- 50-day average
- 22.23
Key statistics
- 200-day average
- 22.89
- Enterprise value
- 21.64B
- PEG ratio
- 0.92
- Price / sales
- 0.54
- Price / book
- 0.73
- Payout ratio
- 50.14%
- Revenue growth
- 1.10%
- Free cash flow
- 1.49B
- Total cash
- 1.10B
- Total debt
- 10.90B
- Return on equity
- 7.84%
Fundamental scorecard
13 of 25 checks passed on FMS’s reported financials
13of 25 checks passed
- Value 5 of 5
- Growth 2 of 5
- Profitability 4 of 5
- Financial health 2 of 5
- Dividend No data
Statements to Sep 30, 2026.
Analyst view
Consensus: hold
- Target (low)
- 15.46
- Target (mean)
- 21.55
- Target (high)
- 34.45
- Strong buy1
- Buy0
- Hold3
- Sell1
- Strong sell2
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.464.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.54 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | 0.651 | 0.64 | -0.01 | -1.69% |
| Aug 3, 2026 | Jun 30, 2026 | 0.616 | 0.66 | +0.04 | +7.14% |
| May 5, 2026 | Mar 31, 2026 | 0.59 | 0.53 | -0.06 | -10.17% |
| Feb 24, 2026 | Dec 31, 2025 | 0.647 | 0.83 | +0.18 | +28.28% |
| Nov 4, 2025 | Sep 30, 2025 | 0.59 | 0.64 | +0.05 | +8.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | Barclays | down | Equal-Weight | Underweight |
| Oct 12, 2026 | Truist Securities | main | Hold | Hold |
| Aug 6, 2026 | Bernstein | main | Market Perform | Market Perform |
| Sep 2, 2025 | UBS | down | Neutral | Sell |
| May 12, 2025 | Truist Securities | main | Hold | Hold |
| Jan 6, 2025 | Truist Securities | main | Hold | Hold |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- Germany
- Website
- freseniusmedicalcare.com
News
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses
Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses
Fresenius Medical Care Q3 2026 Earnings Call Transcript Fresenius Medical Care Affirms FY2026 Sales Guidance of $23.764B vs $22.490B Est
Fresenius Medical Care Q3 Adj. EPS $0.64 Flat Y/Y, Sales $5.682B vs $5.712B Year Ago
Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury
Your note
Sign in to keep a note on FMS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Pzena Investment Management LLC | 3.12% | 16,617,575 | 334.59M | Sep 29, 2026 |
| Morgan Stanley | 0.83% | 4,424,999 | 89.10M | Sep 29, 2026 |
| Dodge & Cox Inc. | 0.63% | 3,328,110 | 67.01M | Sep 29, 2026 |
| Brandes Investment Partners L.P. | 0.37% | 1,969,749 | 39.66M | Sep 29, 2026 |
| Todd Asset Management LLC | 0.33% | 1,761,483 | 35.47M | Sep 29, 2026 |
| TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | 0.21% | 1,106,400 | 22.28M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund | 1.54% | 8,204,589 | 165.20M | Jul 30, 2026 |
| Dodge & Cox Funds-Dodge & Cox Balanced Fund | 0.72% | 3,826,910 | 77.05M | Jun 29, 2026 |
| VANGUARD WHITEHALL FUNDS-Vanguard Selected Value Fund | 0.48% | 2,539,431 | 51.13M | Jul 30, 2026 |
| Liberty All Star Equity Fund | 0.21% | 1,125,292 | 22.66M | Jun 29, 2026 |
| John Hancock Capital Series-Classic Value Fund | 0.18% | 981,665 | 19.77M | Sep 29, 2026 |
| Advisors Series Trust-Pzena U.S. Large Cap Value ETF | 0.02% | 88,224 | 1.78M | Aug 30, 2026 |
